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A B S T R A C T
Purpose: An estimated 1.4 million people in the United Kingdom (UK) have intellectual disability (ID)
with 210,000 having severe or profound ID. Of these, approximately 125,000 have epilepsy, representing
one quarter of all patients with epilepsy in the UK. For those with full scale intellectual quotients (FSIQs)
of less than 50, half have epilepsy, with half of these having treatment resistant epilepsy. One of the two
major causes of mortality within this population is sudden unexpected death in epilepsy (SUDEP).
Methods: We performed a literature review exploring the extent to which ID was considered as a risk
factor for SUDEP. We also considered whether there was any relationship between the types of health
care system in which the studies were conducted and whether ID was considered in studies of SUDEP.
Results: We identiﬁed 49 studies which had explored risk factors for SUDEP, of which, approximately
50% (n = 23) considered ID in the planning stages. Of these studies 60% (n = 14) found ID was a risk factor
for SUDEP. 60% of all the studies were conducted in countries where the health care system was publicly
funded.
Conclusions: Overall we found ID deﬁnitions and speciﬁed standardized mortality rates and impact of
institutionalization to be quite poorly presented.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Epilepsy is a major global health problem affecting an estimated
50 million people worldwide1 and around 400,000 people in the
UK.2 In relatively unselected populations, most studies in both the
developing and the developed world have found the point
prevalence of active epilepsy to lie between 4 and 10/1000; rates
for chronic epilepsy of around 5 to 10/1000 are probably applicable
to all general populations in both the developed and developing
world.3
Many people ﬁnd that their epilepsy does not get in the way of
their everyday life but up to 30% develop treatment resistant
epilepsy.4 Epidemiological studies consistently report a standard-
ized mortality rate (SMR) of 2–4 for epilepsy. In chronic epilepsy* Corresponding author at: Cornwall Partnership NHS Foundation Trust,
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights rethe main cause of excess mortality is death during a seizure in
particular sudden unexpected death in epilepsy (SUDEP). SUDEP is
estimated to account for 500 deaths a year in the UK.5
The incidence of sudden death appears to be 20 times higher in
patients with epilepsy compared with the general population, and
SUDEP is the most important directly epilepsy-related cause of
death. However, the risk varies markedly between different
epilepsy populations. SUDEP is uncommon in patients with new
onset epilepsy and in patients in remission where the incidence
has been estimated to 0.1–0.35 cases in 1000 person years in
population-based cohorts of epilepsy patients. It is considerably
higher in patients with chronic epilepsy, 1–2 per 1000 person
years, and highest among those with severe, refractory seizures, 3–
9 per 1000. SUDEP may occur at all ages, with highest rates
between 20 and 40 years. In most cases SUDEP appears to be
seizure-related.6
SUDEP as a cause of death is obtained by exclusion of other
potential causes. In UK and many other ﬁrst world countries SUDEP
can only be determined by the coroner following an extensive
investigation of the death. The operational deﬁnition for SUDEP isserved.
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deﬁnitive (all 6 criteria of the operational deﬁnition satisﬁed after
an autopsy), probable (Autopsy was not performed but there is no
other plausible explanation for death) and possible (all six criteria
met without an autopsy). Table 1 lists the criteria for classifying
SUDEP deaths.
Various risk factors have been looked for and intellectual
disability (ID) is considered a higher risk though estimates vary.10
Intellectual disability (ID) or Learning disability or mental
retardation is a disability characterized by signiﬁcant limitations in
both intellectual functioning and in adaptive behaviour, which
covers many everyday social and practical skills. This disability
originates before the age of 18 years and persists lifelong.11,12
ID occurs in 2.5–3% of the general population. Standardized
tests need to be undertaken to ascertain the reasoning ability in
terms of mental age which is represented as Intelligent Quotients
(IQ). ID is deﬁned as IQ score below 70–75. Adaptive skills are the
skills needed for daily life and are signiﬁcantly faulty in people
with ID. ID varies in severity. The Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV)12 and the WHO
classiﬁcation system, International Classiﬁcation of Disorders (ICD
10)11 are the diagnostic standards. They classify ID into mild,
moderate, severe, and profound. These categories are based on the
functioning level of the individual. People with mild ID, account for
85% of total ID population, have an IQ range of 55–75 and are
reasonably self-sufﬁcient. Those with moderate ID representing
10% of the total ID population have IQ scores between 35 and
55 manage simple tasks of daily living but struggle with more
complex tasks and require signiﬁcant supervision. About 3–4% of
the ID population is severely impaired. Severe ID individuals have
IQ scores of 20–40. They may master very basic self-care skills and
some communication skills. 1–2% of people with ID who have
profound ID with IQ scores lower than 25 and they lack basic living
skills and/or communication skills. Both severe and profound ID
people need a high level of structure and supervision.
The prevalence of people with ID in the UK is estimated to be
1.4 million.13 26% of patients with epilepsy have ID.14 Half of
patients with IQs of less than 55 i.e. moderate to profound ID have
epilepsy and 50% of these have treatment resistant epilepsy.15 This
population also has a signiﬁcantly higher representation of mental
health and physical health comorbidities and are vulnerable to
both acute and chronic health problems and issues with
communication making it difﬁcult to make informed choices.
The two major epilepsy related causes of death in ID are, sudden
unexpected death in epilepsy (SUDEP) and status epilepticus are
signiﬁcantly over represented in this population.16 With regard to
SUDEP and ID, Tellez-Zenteno et al. in their systematic review
found the risk to be 3.4 times higher than the general population
with epilepsy.17 Walczak et al. in their cohort study identiﬁed a
5 times higher risk of SUDEP, with ID being an independent risk
factor.18 However, in both studies the sample size was quite
limited (n = 5 for IQ < 70). It is therefore uncertain as to whether
intellectual disability is a risk factor for SUDEP. Given that 25%
patients with epilepsy have ID it is therefore important issue toTable 1
SUDEP: sudden unexpected death in epilepsy: deﬁnition and criteria Annegers et
al.8,9
1The victim suffered from epilepsy, deﬁned as recurrent unprovoked seizures
2The death occurred suddenly (in minutes), when known
3The victim died unexpectedly, while in reasonable state of health
4Death occurred during normal activities and benign circumstances
5An obvious medical cause of death was not found
6Death was not directly caused by a seizure or status epilepticus
Deﬁnite = all 6 and autopsy, Probable = all 6, SUDEP autopsy not performed but no
other explanation, Possible = all 6, SUDEP Autopsy not performed and there could be
an alternate explanation.determine if ID is a risk factor for SUDEP to help keep people safe, to
structure person centred services and to manage health costs.
The costs of healthcare in countries which are primarily funded
by personal insurance are high and good insurance coverage is
unaffordable for many. In 2012, The United States Census Bureau
stated that 15.4% of people were uninsured; this infers that
around 48 million people are not satisfactorily covered for
appropriate health care.19 Equally in ‘socialized medicine’
countries such as the UK where the health care is state sponsored
concerns exist of systemic rationing of treatment. Thus the
nature of healthcare adopted by a country could impact
profoundly on managing long term conditions such as epilepsy
in vulnerable people with ID and inﬂuence mortality outcomes.
This paper looks to explore the available evidence of the links
between ID, epilepsy and SUDEP and its links with different
healthcare systems with a view to gaining insights around
current risks and care patterns.
We looked to understand the ID and SUDEP and Epilepsy
connection by investigating
1. Do studies looking at risk factors in SUDEP consider ID?
2. Do studies which look for ID as a risk factor in SUDEP ﬁnd it?
3. Does the type of healthcare funding inﬂuence researchers
exploring ID as a risk factor for SUDEP?
2. Methods
A literature search was undertaken in two phases using all
available data published with no date constraints. The search
included both original research and review articles. Only articles
published in English were used. The review was a detailed
literature review looking into mainstream scientiﬁc literature
available to the search engines mentioned below. It did not take
into account grey literature, unpublished works etc. It was not a
systemic review as speciﬁed by Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA).20
In the ﬁrst phase PubMed was utilized using search terms
‘sudden’ ‘death’, ‘mortality’, ‘epilepsy’, ‘SUDEP’, ‘risk factor’,
‘protective factor’, ‘learning disability’, ‘mental retardation’,
‘neurological impairment’, ‘intelligence’ and ‘intellectual disability’
in different permutations and combinations. Papers were excluded
if they explored only one risk factor for SUDEP such as cardiac
anomalies, intractable epilepsy, asthma and accidental deaths
(drowning and asphyxia) or excluded those with ID. Studies were
not included if they purely examined the paediatric population.
Febrile convulsions were not included.
Articles were deemed appropriate if they either explored at
least one risk factor for SUDEP without excluding the ID population
or had considered a range of possible risk factors for SUDEP.
Microsoft Excel was utilized to record the ﬁndings. Each paper was
examined to see if:
a. When studies were designed did they consider ID as a possible
risk factor?
b. Did the studies deﬁne ID if they included it as a risk factor? Did
they deﬁne ID using International Classiﬁcation of Diseases 1011
or DSM 412 i.e. mild, moderate, severe or profound ID?
c. Did the authors comment on standardized mortality rates?
d. Did any of the studies consider ID as a protective factor? e. Did
the studies ﬁnd ID to be a risk factor for SUDEP A second stage of
exploration then commenced once these questions were
addressed?
We researched what countries the studies were conducted in
and linked it to the type of health care utilized in the country of
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‘Public’ or ‘Dual’ types of healthcare after researching Government
policies online.
 ‘Private’ health care was deﬁned as using a private insurance
based system to provide the majority of the nation’s care.
 ‘Public’ healthcare was deﬁned as the Government providing the
majority of the nation’s care through taxation.
 ‘Dual’ healthcare we have deﬁned as using both private
insurance based as well as state funded healthcare – this
reﬂected varying ratios within countries therefore this is an
umbrella term for countries such as Australia. This was clariﬁed
by reading government ofﬁcial websites.
Descriptive analysis was performed using counts and frequen-
cies. Associations were assessed using Fisher’s Exact test looking at
type of healthcare and whether or not they looked for ID and
whether they found this or not. Statistical signiﬁcance was set at
p < 0.05. Data were analyzed using IBM SPSS statistics for
Windows version 19.21
3. Results
On applying our search strategies, 311 papers were identiﬁed.
Once the exclusion and inclusion criteria were applied, 49 articles
were deemed appropriate and examined. Both original research and
review articles were part of the results and were scrutinized. Care
was taken to include a study only once to avoid duplication. Of the
included studies that explored general risk factors for SUDEP, about
half (n = 23, 46.9%) considered ID in their planning stages. Of the
23 studies which explored ID approximately 60% (n = 14) found it to
be a risk factor for SUDEP (Table 2). Only 2 studies used ICD
10 criteria to deﬁne the nature and degree of ID.18,22 Seven studies
commented on the type of ID.18,22–27 One used the deﬁnition,
‘Intelligent quotient less than 70’18 and another classiﬁed ID as
‘severe or profound’.22 The remaining studies used terms like
‘neurological deﬁcit’,22 ‘enrolled at a residential school’25 or
‘neurodeﬁcit’ deﬁned as mental retardation, cerebral palsy, hypoto-
nia,26 etc. without expanding any further on what they meant by
these terms.
Of the 49 studies examined, 10 (20.4%) studies commented on
Standardized Mortality Rates (SMRs) associated with risk factors in
SUDEP.16,23,25–32,56 The remit of comment and investigation of SMR
of risk factors of these 10 studies was ambiguous and diverse. Some
articles commented on epilepsy SMR in people without ID and
some reported on epilepsy SMR in the background of ID or CP or
neurological damages.
In terms of SMRs related directly to ID as a risk factor, 4 (8%)
studies made speciﬁc comment. Nashef et al. commented that the
standardized overall mortality ratio was 15.9 with 20 of 28 deaths
considered epilepsy related.25 Forsgren et al. found that the SMRTable 2
Summary of results looking at studies exploring ID as a risk factor in SUDEP: sudden
unexpected death in epilepsy





Literature search using stated search terms 311
After exclusion criteria applied2,16–18,22–32,34–60 49
Number of studies which considered ID as a
risk factor in SUDEP2,16–18,22–27,30,31,35,38–42,
45,46,51,55,56
23 46.9
Number of studies which found ID to be a
risk factor in SUDEP16–18,23–27,30,31,41,42,55,56
14 28.6
Number of studies who found ID to be a
protective factor in SUDEP
0for people with epilepsy and ID was as high as 5.0 (95% CI: 3.3–7.5);
if they had cerebral palsy, the SMR increased to 5.8 (95% CI:3.4–9.7)
and the highest mortality (SMR = 8.1; 95% CI: 5.7–11.5) was seen in
those who had a generalized epilepsy from the onset.32 Forsgren30
stated that the highest mortality was found in patients with
epilepsy and ‘neurodeﬁcits’ present since birth, including ID or
cerebral palsy (SMRs ranging from 7 to 50). Sperling32 stated that
the mechanism underlying this increase remains to be elucidated,
but it is consistent with the known high standardized mortality
rates in ID populations.31
Kiani16 studied SUDEP and ID whilst utilizing the Leicestershire
Intellectual Disability Register database between 1993 and 2010.
244 deaths (27%) occurred in people with ID and epilepsy of the
898 adults with ID who had died over the 18-year study period. Of the
109 deaths due to probable or deﬁnite SUDEP in that period across all
populations, 26 (23.4%) were people with ID which was the second
most common cause of death among adults with ID and epilepsy. The
SMRs for SUDEP in patients with ID were 37.6 for men (95% CI: 21.9–
60.2) and 52.0 for women (95% CI: 23.8–98.8). The degree and
aetiology of ID was reported where available but case ﬁles for those
people who died without ID of SUDEP was not analyzed.
The remaining 6 studies made comment about general SMRs in
reference to the other risk factors that they had explored but not ID
speciﬁcally. The studies were conducted in various settings and the
impact of institutionalization on epilepsy in particular and health
in general was not considered by any individual study.
No studies found ID to be a protective factor. However, Duncan
and Brodie24 found that night supervision when associated with ID
was protective. Shankar et al. in their review of SUDEP risk factors
found limited evidence that ID was a risk factor for SUDEP10 but
recognized that this could have been due to poor study designs and
lack of statistical power. Shankar et al. in their 9-year systemic
examination of all SUDEPs in the county of Cornwall identiﬁed only
3 ID patients in 48 SUDEPs. However the presence of a specialist ID
epilepsy service in Cornwall could have inﬂuenced the results
signiﬁcantly.33
The second phase of the literature review considered the
country of origin and the type of healthcare associated with that
country (Table 3).
Of the 49 studies reviewed, approximately 60% (n = 29) were
conducted in countries with publically funded healthcare systems
such as the UK, Sweden and Canada. Fifty ﬁve percent (n = 16) of
publically funded studies (n = 29) considered ID, with 75% (n = 13)
of those considering ID ﬁnding ID to be a risk factor for SUDEP.
Twenty-seven percent (n = 13) of the studies originated from
countries with privately funded healthcare systems like the USA.
Of these 30% (n = 4) considered ID as a risk factor for SUDEP, with
50% (n = 2) ﬁnding this to be the case. Fourteen percent (n = 7) of
the studies were from countries with dual type of healthcare
systems like the Netherlands and Australia. Of these, 43% (n = 3)
explored if ID was a risk factor in SUDEP, with none of these studies
ﬁnding it to be (Table 3).
Analysis of the above data showed that the undertaking of
investigation of ID as a potential risk factor by the examined
studies (n = 23) did not depend on the type of health care system
from which the studies originated (p = 0.173). However, when the
papers (n = 23) were examined to see if there was association
between the type of healthcare and their ﬁnding of ID as a risk
factor, papers emerging from publicly funded health systems were
more likely to ﬁnd ID as a risk factor than either dual or private
health systems (p = 0.040).
4. Discussion
The premature mortality in particular SUDEP caused by
epilepsy is a subject of topical importance. The literature on
Table 3
Summary of studies (N) who looked for and found ID as a risk factor in SUDEP: sudden unexpected death in epilepsy.
Type of healthcare n = 49 Looked for ID
(N = 23)
% of total Found ID n = 14 % of total
(n = 23)
Private18,22,26,31,32,48,49,54,59,62,64–66 13 418,22,26,31 17 218,31 8.69
Public2,16,17,23–25,27–30,34,36,39–43,45,47,
50–53,55–57,60,63,67
29 162,16,17,23–25,27,30,39–41,43,45,51,55,56 70 1216,17,23–25,27,30,41,42,45,55,56 52.1
Dual35,37,38,44,46,58,61 7 335,38,46 13 0 0
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though overrepresented in patients with epilepsy has not been
looked at in any sufﬁcient detail to enumerate its risk for SUDEP.
This is conﬁrmed by the fact that when looked for by researchers it
has come up as a signiﬁcant factor. Studies in the literature
searched appeared to vary in their interest in exploring the role of
ID within SUDEP. From the little research available the ID
population is more impacted by the consequences of epilepsy
including SUDEP. Donoghue et al. stated that the general risk of
SUDEP for people with epilepsy was between 1:500 and 1:1000
person-years. Donoghue et al. goes on to explain that the risk
increases to 1:200 person years for those with a neurological
impairment.27
The over representation of SUDEP in the ID population is a
major issue of concern.16 The cognitive impairment and commu-
nication difﬁculties intrinsic to ID could leave many people with ID
vulnerable to difﬁculties in making informed choices around
treatment. In addition they could have poor understanding of the
potential interventions and investigations (such as EEG, blood
tests, etc.). They are also predisposed to higher levels of distress
and anxiety leading to potential behaviour disturbances. Thus
assessment and diagnosis due to these considerations are made
signiﬁcantly more difﬁcult and leaves the vulnerable individual
exposed to misdiagnosis and potential inadvertent harm. Unfor-
tunately very few studies explore ID as a risk factor and fewer still
analyze its impact.
Epilepsy occurs at a higher incidence and is more prevalent in
people with an intellectual disability. It is well recognized that
health and social needs and their outcomes for people with ID vary
signiﬁcantly based on their level of ID. This makes it important to
know if differentiation was made between mild, moderate, severe
and profound ID as is current good practice when health and social
care is delivered. No study has looked satisfactorily into this issue.
The majority of studies of SUDEP and ID have been focused on
presence or absence of ID and not looked at issues from the
perspective of the organization and availability of health and social
services for people with ID.
It appears the research of ID being examined as a risk factor for
SUDEP is not skewed by the nature of healthcare systems across
the globe. However we are mindful that given the small number of
studies available there is scope of a potential type 2 error due to
lack of power. When studies examine for ID as a risk factor it
appears public supported health systems are more likely to ﬁnd
them than private or mixed care health systems. While on the face
of it this suggests more representation of people with ID in the
SUDEP deaths in public health systems it is difﬁcult to hypotheses’
this with any conﬁdence given the potential bias of unclear
deﬁnition, poor and unclear case selections and low power.
The data on the health system is weak and given to potential error
in interpretation. Firstly the methodology used was an indirect
representation of the nature of health care (i.e. using classiﬁcation
based on origin of scientiﬁc papers). Secondly the number of studies
which discuss SUDEP let alone ID and SUDEP is far from satisfactory.
Thirdly, the type of care the patients got was not looked into.
However, it illuminates and interesting unsearched area in the care
of people with ID and epilepsy.A major associated area not looked at by any of the studies was
the confounding effects of institutionalization and inherent
cognitive impact of epilepsy. There is robust evidence68 to suggest
that prolonged institutionalization has an impact on intellectual,
physical, behavioural, and social–emotional functions leading to a
range of children and people who would not have an inherent ID
sublimating to a range of ID functioning.
As all of the studies looked at people dead as a result of SUDEP it
is a matter of concern that ID was not thought relevant enough or
the individuals suspected to have ID not further investigated to
examine comprehensively for nature and degree of ID. This reﬂects
a possible professional gap and lack of comprehension of issues of
ID in investigating teams which pre-dominantly were of neuro-
logical origin. People with ID are living longer and various good
practice charters13 exist to ensure they have equal rights as any
other citizen of their country. However fundamental gaps exist in
the care provided, led by ignorance and indifference69.
Known areas of high medical risk, such as epilepsy which is
signiﬁcantly over represented in ID population needs to be handled
in a person centred and proactive manner in vulnerable adults with
ID. Three potential models of enabling this in research and care
settings could be suggested. Clinicians and researchers working in
Epilepsy could avail bespoke training on ID speciﬁc issues
including skill development in mental capacity issues, communi-
cation issues and frequent co-morbidities (such as sensory
problems, Autism, behavioural disturbances, etc.). There could
be involvement of ID professionals in developing epilepsy studies
and models of care. Alternately, ID clinicians could be up skilled
with epilepsy competencies. However, the best results could be a
mix of all three where there is strong conjoined working between
Epilepsy and ID professionals at both research and clinical care
levels. A broad based multi-professional development of skills with
shared competencies would signiﬁcantly protect and risk mini-
mize vulnerable individuals with ID from the devastating
consequences of Epilepsy such as SUDEP.
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